Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the association of rheumatologists of Russia
E. L. Nasonov,A. M. Lila,Vadim I. Mazurov,B. S. Belov,A. E. Karateev,Tatiana Dubinina,O. A. Nikitinskaya,A. A. Baranov,Diana Abdulganieva,S. V. Moiseev,A. I. Zagrebneva +10 more
- Vol. 59, Iss: 3, pp 239-254
Reads0
Chats0
TLDR
The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.Citations
More filters
Journal ArticleDOI
Деплеция в-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (covid-19)
Е. Л. Насонов,А. С. Авдеева +1 more
TL;DR: According to the recommendations of the Association of Rheumatologists of Russia, a more rigorous assessment of indications for induction and maintenance therapy of RTX therapy and harmonization of the timing of drug administration and vaccination is required.
Journal ArticleDOI
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
TL;DR: The frequency of exacerbation of RD after vaccination against COVID-19 seems to be quite low (5–7%) and has no significant associations with a specific vaccine or anti-rheumatic therapy, and unambiguous interpretation is difficult.
Journal ArticleDOI
Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
Evgeny Nasonov,T.V. Korotaeva +1 more
TL;DR: The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.
Journal ArticleDOI
Rheumatoid arthritis and post-COVID-19 syndrome
TL;DR: It is thought that SARS-CoV-2 infection may be a trigger factor for new rheumatic musculoskeletal diseases, including rheumatoid arthritis or COVID-19 can unmask previously undetected RA, and arthritis in the post covid period may induce problems in differential diagnosis of rhematic diseases.
Journal ArticleDOI
Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data)
TL;DR: Preliminary data suggest that vaccination against COVID-19 in patients with IRD appears to be quite safe, and further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of CO VID-19 immunization in rheumatic patients.
References
More filters
Journal ArticleDOI
Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis.
Dipayan Chaudhuri,Kiyoka Sasaki,Aram Karkar,Sameer Sharif,Kimberly Lewis,Manoj J. Mammen,Paul E. Alexander,Zhikang Ye,Luis E. Colunga Lozano,Marie Warrer Munch,Anders Perner,Bin Du,Lawrence Mbuagbaw,Lawrence Mbuagbaw,Waleed Alhazzani,Stephen M. Pastores,John Marshall,Francois Lamontagne,Djillali Annane,Gianfranco Umberto Meduri,Bram Rochwerg,Bram Rochwerg +21 more
TL;DR: The use of corticosteroids probably reduced mortality in patients with ARDS of any etiology (2740 patients in 16 trials, RR 0.82, 95% CI 0.72-0.95, ARR 8.0%, 95%CI 2.2-12.5%, moderate certainty).
Journal ArticleDOI
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
TL;DR: In this paper, the authors have assessed antibody response and T cell mediated immune response to the BNT162b2 (Pfizer/BioNTech) vaccine in patients undergoing rituximab (RTX) treatment at the end of the treatment interval.
Posted ContentDOI
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report
TL;DR: Tocilizumab and Sarilumab both met the pre-defined triggers for efficacy as discussed by the authors, yielding >99.9% and 99.5% posterior probabilities of superiority compared with control.
Journal ArticleDOI
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.
TL;DR: PsO patients on biologics should be carefully monitored with telemedicine during COVID‐19 outbreak and early treated at home to limit hospital overwhelm and increased risk of ICU admission or death were found.
Journal ArticleDOI
COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study.
Kristin M. D’Silva,April Jorge,Andrew Cohen,Natalie McCormick,Yuqing Zhang,Zachary S. Wallace,Hyon K. Choi +6 more
TL;DR: Patients with systemic autoimmune rheumatic diseases (ARDs) continue to be concerned about risks of severe coronavirus disease 2019 (COVID‐19) outcomes, but patients without systemic ARDs are not as concerned.